Clinical trial · Interventional
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no "testosterone surge" after leuprolide injection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Degarelix acetate, Leuprolide acetate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- ADT
- description
- All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
- interventionNames
- Drug: Degarelix acetate, Leuprolide acetate
Primary outcomes (1)
- measure
- Testosterone measurement
- timeFrame
- 11 times over 6 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older * Histologically confirmed adenocarcinoma of the prostate * Androgen deprivation therapy is indicated Exclusion Criteria: * Baseline screening serum testosterone \<150ng/dL * Eastern Cooperative Oncology Group (ECOG) score \> 2 * Diagnosed spinal or brain metastases * Hormonal manipulation within previous 6 months
References
Publications (0)
Data not yet available